• Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead Realasset

Presented by :

Associate Sponsor :

Home » News » Business

May 17, 2013, 01.46 PM | Source: Moneycontrol.com

Drug pricing regime comes into effect; pharma stocks mixed

The Department of Pharmaceuticals on Thursday notified Drug Price Control Order 2013. Once implemented over next few months, prices of 348 essential drugs will come down. Market reaction was mixed with firms like Cipla, Sun Pharma, Ranbaxy, Lupin and Glenmark down 0.5-2%.

Like this story, share it with millions of investors on M3

Drug pricing regime comes into effect; pharma stocks mixed

The Department of Pharmaceuticals on Thursday notified Drug Price Control Order 2013. Once implemented over next few months, prices of 348 essential drugs will come down. Market reaction was mixed with firms like Cipla, Sun Pharma, Ranbaxy, Lupin and Glenmark down 0.5-2%.

Post Your Comments

Share Cancel

Moneycontrol Bureau

Pharma stocks were trading mixed on Friday, with the likes of Cipla , Sun Pharma , Ranbaxy , Lupin , Glenmark and Dr Reddy's down 0.5-2 percent in morning trade. Multi-national players like Pfizer , Wyeth and GlaxoSmithKline were up 0.2-0.5 percent. The Department of Pharmaceuticals on Thursday notified the much awaited Drug Price Control order 2013.

Once implemented, prices of 348 essential drugs will reduce; prices of drugs are likely to come down by average 20-25 percent.

The new pharma pricing policy will be implemented over the next few months. Companies will be given 45 days to clear existing inventory and adjust product prices after ceiling prices are notified based on the simple average formula.

Also Read: Ex Citi boss Vikram Pandit to lead JM Fin banking foray

"Pricing control is likely near-term negative for most stocks, though more so for MNCs, though we believe the stocks are already pricing in market-based mechanism to quite an extent," according to a foreign brokerage.

It further says that downgrades for MNCs will be larger as their revenue comes from the Indian market, products are premium priced and their exposure is higher to the actue therapy segments, where more drugs are in the essential list.

The brokerage expects "moderate" impact on Cipla and Cadila Healthcare with potentially 8-10 percent earnings downgrades. Sun Pharma and Lupin, meanwhile, are likely to be least impacted by the policy and have strong "tailwinds" from the US business, it adds.

Cipla stock price

On February 12, 2016, Cipla closed at Rs 528.60, down Rs 12.4, or 2.29 percent. The 52-week high of the share was Rs 752.45 and the 52-week low was Rs 518.00.


The company's trailing 12-month (TTM) EPS was at Rs 19.63 per share as per the quarter ended December 2015. The stock's price-to-earnings (P/E) ratio was 26.93. The latest book value of the company is Rs 137.93 per share. At current value, the price-to-book value of the company is 3.83.

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Drug pricing regime comes into effect; pharma stocks mixed

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login